HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 18 and 24 years old
- People who were assigned male sex at birth
- People who identify as a gay or bisexual man, or as a transgender woman or another gender identity along the feminine spectrum
- People who are living with HIV, as confirmed by their medical records
- People who are currently taking or have been prescribed HIV treatment (antiretroviral therapy) for more than 3 months
- People who have missed 2 or more doses of their HIV medication in any single week during the past month, OR whose HIV is not currently at undetectable levels in their blood (confirm with trial site for exact measurement details)
- People who own a mobile phone or are willing to use one as part of the study
Who may not be able to join:
- People who are unable to give informed consent due to a cognitive limitation, a severe mental or physical illness, or being under the influence of substances at the time of consent
- People whose ability to read and/or write would make it too difficult for them to understand the informed consent documents
- People who have lived in the greater Rio de Janeiro area for less than 3 months, or who are planning to move outside of that area within the next year
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Katie Biello, PhD, MPH, Brown University
Phone: 4018634082
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility: number of participants who have at least one follow up visit; Feasibility: mean number of intervention sessions attended; Acceptability: mean score on the Client Satisfaction Questionnaire scale (CSQ-8); Medication adherence - proportion of participants with presence of tenofovir in urine using a point-of-care lateral flow immunoassay (LFA) method; Medication adherence - proportion who have received all ART prescriptions over the course of follow up according to pharmacy dispensing records (SICLOM national registry)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.